Enzon Pharmaceuticals, Inc. is engaged in licensing drug products. The company receives royalties on six marketed drug products that utilize its proprietary PEGylation platform, namely PegIntron, Sylatron, Macugen, CIMZIA, Oncaspar and Adagen, with PegIntron being the major source of its royalty income. The company’s marketed drug products include PegIntron for chronic hepatitis C; Sylatron for Melanoma; Macugen for neovascular age-related macular degeneration; CIMZIA for Crohn’s disease; Oncaspar for acute lymphoblastic leukemia; and Adagen for severe combined immunedeficiency. The company has out-licensed its proprietary PEGylation and single-chain antibody, technologies on its own and through agreements with Nektar Therapeutics, Inc. and Micromet AG. Macugen is being marketed by Valeant Pharmaceuticals Inc. in the U.S. and by Pfizer Inc. in the rest of the world. The company has a collaboration agreement with Zhejiang Hisun Pharmaceutical Co., Ltd. (Hisun) pursuant to which it licensed to Hisun exclusive development and commercialization rights for PEG-SN38 in China. Competition The company competes with Hoffmann-La Roche; Bayer; Bristol-Myers Squibb Company; Valeant Pharmaceuticals Inc.; Pfizer Inc.; UCB Pharma; Takeda; Affymax; and Amgen, Inc. History Enzon Pharmaceuticals, Inc. was founded in 1981.
enzon pharmaceuticals inc
(ENZN:Consolidated Issue listed on NASDAQ Capital Market)
20 Kingsbridge Road
Piscataway, NJ 08854
|Abzena PLC||82.00 GBp||0.00|
|Depomed Inc||$23.65 USD||+0.66|
|Emergent Biosolutions Inc||$29.48 USD||+0.61|
|Veloxis Pharmaceuticals A/S||kr0.94 DKK||0.00|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ENZON PHARMACEUTICALS INC, please visit www.enzon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.